Eliminate problematic polymorphs and fast-track stable solid forms with X-ray powder diffraction

Progressing drug development without fully understanding the structure and stability of polymorph variants can quickly lead to potential safety, efficacy or quality issues. Gaps in polymorph profiling can also lead to ambiguity in patent applications, which can have disastrous consequences even years into a drug product’s lifecycle. A clear understanding of an API and all its forms - through solid form analysis - could improve the chances of regulatory approval, decrease the time required to get a drug product to market, and protect potential revenues.

This guide explores the use of X-ray powder diffraction (XRPD) as a powerful tool to develop and improve pharmaceutical formulations and ensure quality standards are met throughout the drug development workflow. 


Not registered yet? Create an account